Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Islet Studies

Inducible and Reversible β-Cell Autoimmunity and Hyperplasia in Transgenic Mice Expressing a Conditional Oncogene

  1. Irina Berkovich and
  2. Shimon Efrat
  1. Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Diabetes 2001 Oct; 50(10): 2260-2267. https://doi.org/10.2337/diabetes.50.10.2260
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Figures

    • FIG. 1.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 1.

      Tag expression in newborn RIP7-rtTA × tet-Tag double-transgenic mice. Sections of the pancreas from double-transgenic newborn mice born to females treated with dox from early pregnancy (A) or untreated (B) were immunostained for Tag. Magnification is 375×.

    • FIG. 2.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 2.

      Islet β-cell proliferation is dependent on Tag expression. Mice were treated with dox starting from embryonic development until 5 weeks of age (A and B) or until 4 weeks of age, followed by 1 week in the absence of dox (C and D). Pancreas sections were immunostained for Tag (A and C) and BrdU (B and D). Magnification is 113×.

    • FIG. 3.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 3.

      Insulitis induced by late onset of Tag expression and reversed by shut-off of Tag expression. Double-transgenic RIP7-rtTA × tet-Tag mice were treated with dox starting at 3 weeks of age. HE staining of pancreas sections at 8 weeks of age revealed insulitis in the islets (A). The area of cell infiltration is devoid of insulin immunostaining in an adjacent section (B). Insulitis did not delay the formation of insulinomas by 12 weeks of age (C and D, HE staining). In mice in which dox treatment was terminated at 8 weeks of age, no insulitis was visible in the majority of the islets by 12 weeks (E and F, HE staining). Arrows mark areas of insulitis. Broken lines mark tumor boundaries. Magnification is 49× (A and B), 16× (C and E), and 139× (D and F).

    • FIG. 4.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 4.

      Reversibility of insulitis after shut-off of Tag expression. Double-transgenic RIP7-rtTA × tet-Tag mice were treated with dox between 3 and 8 weeks of age. Pancreas histology was analyzed at the indicated time points after dox removal. The number of islets with insulitis is expressed as a percent of the combined total islet number in 3–4 mice analyzed at each time point (except for the 6-week time point, at which time 10 mice were scored) .

    • FIG. 5.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 5.

      Islet cell apoptosis in RIP7-rtTA × tet-Tag mice during Tag expression and after shutoff of Tag expression. Double-transgenic mice were treated with dox between 3 and 8 weeks of age. The pancreas was removed at the termination of dox treatment (A and B) or after 3 (C and D) or 4 (E and F) additional weeks in the absence of dox. Pancreas sections were analyzed by HE staining (A, C, and E) and by a TUNEL assay for apoptotic cells in adjacent sections (B, D, and F). Arrows in A and B mark areas of insulitis. Magnification is 49× (A and B), 65× (C and D), and 194× (E and F)

    • FIG. 6.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 6.

      Decrease in islet cell apoptosis after shut-off of Tag expression. Mice treated with dox between 3 and 8 weeks of age were analyzed at the indicated time points after dox removal. Pancreas sections were stained for apoptotic cells by a TUNEL assay. Labeled nuclei were counted in pancreas sections of 3–4 mice for each time point (except for the 6-week time point, at which 10 mice were scored). Ten average-size islets similar in size to those shown in Fig. 5D, each containing several hundred cells, were scored in each pancreas. Values are expressed as a percentage of the total cell number in the islets scored and represent the means ± SE.

    • FIG. 7.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 7.

      Persistence of hyperplastic islets lacking proliferating and apoptotic cells in some RIP7-rtTA × tet-Tag mice. Mice treated with dox between 3 and 8 weeks of age were analyzed at 16 weeks of age. Pancreas sections were stained with HE (A), Tag antibody (B), and BrdU antibody (C) and were analyzed in a TUNEL assay (D). Magnification is 66×.

    PreviousNext
    Back to top

    In this Issue

    October 2001, 50(10)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Inducible and Reversible β-Cell Autoimmunity and Hyperplasia in Transgenic Mice Expressing a Conditional Oncogene
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Inducible and Reversible β-Cell Autoimmunity and Hyperplasia in Transgenic Mice Expressing a Conditional Oncogene
    Irina Berkovich, Shimon Efrat
    Diabetes Oct 2001, 50 (10) 2260-2267; DOI: 10.2337/diabetes.50.10.2260

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Inducible and Reversible β-Cell Autoimmunity and Hyperplasia in Transgenic Mice Expressing a Conditional Oncogene
    Irina Berkovich, Shimon Efrat
    Diabetes Oct 2001, 50 (10) 2260-2267; DOI: 10.2337/diabetes.50.10.2260
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
    • Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with KATP Channels
    • Pancreatic β-Cell–Specific Deletion of VPS41 Causes Diabetes Due to Defects in Insulin Secretion
    Show more Islet Studies

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.